Figure 3.
(A) Relative risks of sustained conversion at 24 h in trials comparing vernakalant to comparator in patients with recent-onset atrial fibrillation: all participants. (B) Relative risks of sustained conversion at 24 h in trials comparing vernakalant to comparator in patients with recent-onset atrial fibrillation: participants who converted acutely.
